摘要
目的探讨匹多莫德佐治新生儿出生后感染性肺炎的临床疗效及免疫功能变化。方法设正常新生儿组(n=30),匹多莫德治疗组(n=30),常规治疗组(n=30)。比较匹多莫德治疗组,常规治疗组两组患儿治疗后的临床疗效,检测两组治疗前后的免疫抗体及T淋巴细胞亚群的变化。结果匹多莫德治疗疗效优于常规治疗组(P<0.05),两组新生儿出生后感染肺炎患儿CD3、CD4T淋巴细胞较正常新生儿组下降(P<0.05)CD4/CD8比值亦降低(P<0.05),经治疗匹多莫德治疗组CD3、CD4T淋巴细胞恢复正常,与正常新生儿组无显著差异性(P>0.05)。常规治疗组经治疗CD3、CD4T淋巴细胞,CD4/CD8比值有改善,但仍低于对照组(P<0.05).匹多莫德治疗组及常规治疗组IgA低,治疗后有升高(P<0.05),治疗前IgM升高,治疗后IgM继续升高。结论匹多莫德可通过增强免疫功能来提高治疗新生儿出生后感染性肺炎的疗效。
Objective To observe the clinical therapeutic effect and immune function changes of Pidotimod′s preventing and treating infectious pneumonia in newborn patients. Methods Pidotimod′s treatment group （n=30）, conventional treatment group （n=30）. compared the clinical curative effect of the two groups after treatment, to test immune antibodies and T lymphocyte subsets of change before and after treatment between the two groups. Results the curative effect of the Pidotimod cure group was better than conventional treatment group （P＆lt;0.05）, T lymphocyte （CD3, CD4）of two groups of newborn patients was less than normal lymphocyte newborn （P＆lt;0.05）, CD4/CD8 ratio also reduce （P＆lt;0.05）. After the treatments, in Pidotimod cure groups the T lymphocyte （CD3, CD4） was back to normal, and no signiifcant difference of normal babies （P＆gt;0.05）;In conventional treatment group, CD4/CD8 ratio had improved, but still lower than those of the control group （P＆lt;0.05）. IgA was low before treatment in Pidotimod′s treatment group and conventional treatment group but had improved after treatment（P＆lt;0.05）, IgM was high Before treatment and continued to rise after treatment. Conclusion Pidotimod can improve curative effect of the treatment of infectious pneumonia after the baby is born by enhancing immune function.
出处
《中国医药指南》
2014年第5期15-15,17,共2页
Guide of China Medicine
